Layers of protection around a product
The compound itself is often claimed first, with later filings on formulations, dosing regimens, methods of treatment, manufacturing processes, and crystal forms. Each layer has its own filing date and term, and later layers are frequent targets for challenges arguing they add nothing inventive. FDA regulatory exclusivities, such as those tied to new chemical entities or orphan designation, are separate from patents and can protect a product even where patents are weak. Patent term extension can restore part of the time lost during regulatory review, generally for a single patent per approved product and subject to limits, and the application has to be filed within a short window after approval.
Orange Book and Purple Book listings
For small-molecule drugs, the brand company lists qualifying patents in FDA's Orange Book, and those listings set up the framework under which generic filers certify against them and litigation can begin. Listing decisions carry risk: the FTC has publicly challenged listings it considers improper, including some device patents listed for drug-device combinations. Biologics follow a different system, with patent information exchanged with biosimilar applicants and published in FDA's Purple Book. Teams handling regulatory filings and patent prosecution need to share information, because statements made to one agency can be quoted against the company before the other.
Where the first review starts
Generic and biosimilar challengers often study a patent estate long before launch, through prior art searches, inter partes review petitions, and close reading of statements made during prosecution. Brand companies do well to look at their own portfolio the same way, and early. Bring the patent list, the expected approval timeline, the regulatory exclusivities claimed, and any licensing agreements with universities or partners that control prosecution. We review which patents cover the product as it will actually be marketed, where gaps exist, and which follow-on filings remain possible. Settlements of patent challenges with generic companies can draw antitrust scrutiny, so their terms deserve attention from the start.
